Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group is a research paper published in Cancer Discovery (2024). On theSindex it has a DataRank of 0.590. It has been cited 16 times, with 15 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.425
From this paper's citation signal
Citation Network Contribution
0.165
From 7 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 15 citers.
National Cancer Institute
Grant: 1U54CA196519
National Cancer Institute
Grant: R37CA266550
National Cancer Institute
Grant: U10CA180886
National Cancer Institute
Grant: U10CA180899
Alex’s Lemonade Stand Foundation for Childhood Cancer
Grant: Center of Excellence
NCI NIH HHS
Grant: P30 CA015704
NCI NIH HHS
Grant: U54 CA196519
NCI NIH HHS
Grant: P30 CA082709
NCI NIH HHS
Grant: R50 CA274213
St. Baldrick's Foundation (SBF)
St. Baldrick’s Foundation
FWCI
4.53
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals